| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont and 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Requests for reprints: Marcus Bosenberg, Department of Pathology, University of Vermont College of Medicine, 323 Health Science Research Facility, 149 Beaumont Avenue, Burlington, VT 05405. Phone: 802-656-0309; Fax: 802-656-8892; E-mail: marcus.bosenberg{at}uvm.edu.
Malignant melanoma is a common and frequently lethal disease. Current therapeutic interventions have little effect on survival, emphasizing the need for a better understanding of the genetic, epigenetic, and phenotypic changes in melanoma formation and progression. We identified 17 genes that were not previously known to be silenced by methylation in melanoma using a microarray-based screen following treatment of melanoma cell lines with the DNA methylation inhibitor 5-Aza-2'-deoxycytidine. Eight of these genes have not been previously shown to undergo DNA methylation in any form of cancer. Three of the genes, QPCT, CYP1B1, and LXN, are densely methylated in >95% of uncultured melanoma tumor samples. Reexpression of either of two of the silenced genes, HOXB13 and SYK, resulted in reduced colony formation in vitro and diminished tumor formation in vivo, indicating that these genes function as tumor suppressors in melanoma. (Cancer Res 2006; 66(23): 11187-93)
This article has been cited by other articles:
|
|
 |
|
  Y. Koga, M. Pelizzola, E. Cheng, M. Krauthammer, M. Sznol, S. Ariyan, D. Narayan, A. M. Molinaro, R. Halaban, and S. M. Weissman Genome-wide screen of promoter methylation identifies novel markers in melanoma Genome Res., August 1, 2009; 19(8): 1462 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, U. Shrikhande, B. M. Alicie, Q. Zhou, and R. L. Geahlen Role of the Protein Tyrosine Kinase Syk in Regulating Cell-Cell Adhesion and Motility in Breast Cancer Cells Mol. Cancer Res., May 1, 2009; 7(5): 634 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bailet, N. Fenouille, P. Abbe, G. Robert, S. Rocchi, N. Gonthier, C. Denoyelle, M. Ticchioni, J.-P. Ortonne, R. Ballotti, et al. Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth Arrest Cancer Res., April 1, 2009; 69(7): 2748 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S.M. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, A. J. King, K. T. Flaherty, M. Bosenberg, M. Herlyn, et al. Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression Cancer Res., July 15, 2008; 68(14): 5743 - 5752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A.T. Rodriguez, A. S.L. Cheng, P. S. Yan, D. Potter, F. J. Agosto-Perez, C. L. Shapiro, and T. H.-M. Huang Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer Carcinogenesis, July 1, 2008; 29(7): 1459 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, Y. Gong, J. Yue, B. Qiang, J. Yuan, and X. Peng Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing Nucleic Acids Res., June 1, 2008; 36(11): 3590 - 3599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Anderton, J. C. Lindsey, M. E. Lusher, R. J. Gilbertson, S. Bailey, D. W. Ellison, and S. C. Clifford Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2 Neuro-oncol, January 1, 2008; 10(6): 981 - 994. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
